Immunotherapy & AI for first-line soft tissue sarcoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have one of the listed sarcoma types (e.g., undifferentiated sarcoma, synovial sarcoma, angiosarcoma, etc.) that is locally advanced (cannot be removed by surgery or radiation) or has spread/come back.
- You should be in generally good health (able to do daily activities, like walking and self-care) with an ECOG score of 0 or 1.
- You cannot have had prior treatment for advanced sarcoma, unless you received chemotherapy after surgery and then relapsed more than 6 months later.
- You must not have active autoimmune diseases, uncontrolled infections, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Hear when a new Angiosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.